IL13RA2 and glioblastoma: A landmark case demonstrated a complete response in recurrent multifocal glioblastoma during a clinical trial using multiple intracavitary and intraventricular infusions of IL13Rα2-specific CAR-T cells, highlighting the viability of repeated locoregional treatment [122].